BAT Sells 3.5% Stake in ITC for $2.1 Billion

BAT by 2FIRSTS.ai
Mar.14.2024
BAT Sells 3.5% Stake in ITC for $2.1 Billion
British American Tobacco (BAT) sells 3.5% stake in India's ITC Ltd for $2.1 billion, retaining 25.5% ownership.

According to a report from the Indian media outlet Theweek, British American Tobacco (BAT) sold a 3.5% stake in Indian Tobacco Company (ITC Ltd) through a public market transaction on March 13, with the total transaction amount reaching 174.85 billion rupees ($2.1 billion USD).

 

Despite completing this major transaction, BAT remains an important shareholder of ITC, holding a 25.5% stake in the company. Other shareholders of ITC include the Singapore government, Singapore Monetary Authority, Lockheed Martin Corporation, Goldman Sachs (Singapore), Copthall Mauritius Investments, BofA Securities Europe SA, Societe Generale, Morgan Stanley Asia Singapore Limited, and Ghisallo Master Fund LP.

 

BAT has sold over 436.8 million equity shares through its subsidiary India Tobacco Manufacturers (India) Ltd, in 48 transactions, equivalent to a 3.5% stake in ITC. The average selling price for these shares was 400.25 Indian rupees per share, with a total transaction value of 174.85 billion Indian rupees.

 

Over 30 institutions purchased shares in this sale, including ICICI Prudential Mutual Fund, Motilal Oswal MF, Nippon India MF, SBI MF, Max Life Insurance Company, IMF, Capital Group, Kuwait Investment Authority, The People's Bank of China, and International Bank for Reconstruction and Development.

 

It is reported that BAT plans to use the net proceeds from this bulk transaction to buy back its own shares by December 2025, starting as early as 2024, with a total amount of up to 700 million pounds. In addition, BAT will continue to use operating cash flow to fund its transformation and further reduce debt.

 

The initial investment by BAT in ITC can be traced back to the early 20th century, with both companies maintaining a mutually beneficial relationship for an extended period of time.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report| Vuse Gains as U.S. Cracks Down on Illegal Vapes, But a $590 Million China Export Shadow Looms
Special Report| Vuse Gains as U.S. Cracks Down on Illegal Vapes, But a $590 Million China Export Shadow Looms
The payoff is here: BAT’s Vuse has seized a rare regulatory vacuum to reverse its U.S. slide, capitalizing on a crackdown that seemingly compressed the illicit market to 54%. But the victory is fragile. A record $590 million export shock in October signals the gray market is striking back—pitting a fleeting compliance dividend against a massive inventory wall.
BAT
Dec.09
Singapore Schools Enhance Anti-E-cigarette Education with Scenario Discussions and Scientific Evidence
Singapore Schools Enhance Anti-E-cigarette Education with Scenario Discussions and Scientific Evidence
Singapore schools are ramping up anti-vaping education through Character and Citizenship Education (CCE) and science lessons. Classes now use scenario-based discussions—for example, a friend asking you to hide their vape during a random bag check—to help students practise refusal, empathy and seeking help safely.
Oct.22 by 2FIRSTS.ai
Study: TikTok Content Frames Nicotine Pouches as “Trendy Accessories,” Diluting Risk Perception Among Youth
Study: TikTok Content Frames Nicotine Pouches as “Trendy Accessories,” Diluting Risk Perception Among Youth
A study published in JMIR Formative Research analyzed 132 TikTok videos related to nicotine pouches and found that platform content predominantly presents these products as a “youthful trend” rather than as smoking cessation tools. Health risks are underrepresented, the user base appears largely male, and this portrayal may influence how adolescents perceive the risks associated with nicotine products.
Dec.04 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
Following Japan debut, IQOS ILUMA i “Seletti Edition” limited series launches in South Korea.
Following Japan debut, IQOS ILUMA i “Seletti Edition” limited series launches in South Korea.
Philip Morris International (PMI) Korea announced a collaboration with Italian design brand Seletti to launch the IQOS ILUMA i limited “Seletti Edition.” Pre-sales begin on the 29th at IQOS.com for IQOS Club Gold and Platinum members, with sales from the 30th via the website and nine IQOS-owned stores nationwide. PMI previously said the series would debut in Japan first before rolling out to 13 global travel-retail markets.
Oct.29 by 2FIRSTS.ai
FDA CTP Acting Director  Supports Expanding Authorized Flavored E-Cigs and Legal Marketplace
FDA CTP Acting Director Supports Expanding Authorized Flavored E-Cigs and Legal Marketplace
At the FDLI Tobacco and Nicotine Policy Conference, FDA CTP Acting Director Bret Koplow spoke in favor of promoting tobacco harm reduction to reduce smoking. He backed a legal marketplace for authorized reduced-risk products, potential expansion of flavored e-cigs, and faster FDA reviews to ensure a strong, regulated market.
Oct.29 by 2FIRSTS.ai